SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain 3.9% Passive Stake in Bicara Therapeutics

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.9% of Bicara Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in BICARA THERAPEUTICS INC.
• As of December 31, 2024, FMR LLC and Abigail P. Johnson collectively beneficially own 2,117,088 shares of BICARA THERAPEUTICS INC. Common Stock.
• This aggregate amount represents 3.9% of the class of securities.
• FMR LLC holds sole voting power over 2,116,973 shares and sole dispositive power over 2,117,088 shares.
• Abigail P. Johnson holds sole dispositive power over 2,117,088 shares, with no sole or shared voting power.
• The filing indicates that the securities were acquired and are held for passive investment purposes, not for changing or influencing the control of the issuer.
• FMR LLC is identified as a parent holding company or control person, and Abigail P. Johnson is identified as an individual.
• The filing was signed on February 11, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing passive beneficial ownership. It does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook, but rather reflects an institutional investment.

Positives

• The document indicates continued institutional investment in Bicara Therapeutics Inc. by FMR LLC, a major asset manager, and Abigail P. Johnson, a key figure within FMR LLC.

Negatives

• The Schedule 13G filing is a routine disclosure of ownership and does not inherently contain negative information regarding the issuer's performance or outlook.

Risks

• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating the risk of an activist or hostile takeover attempt from this specific party.

Future Outlook

The document is a disclosure of past beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates that a significant institutional investor, FMR LLC (Fidelity), continues to hold a passive stake in Bicara Therapeutics Inc., a company operating in the biotechnology sector. Such institutional holdings are common and can signal investor confidence, though this specific filing is a routine disclosure of ownership rather than a strategic announcement.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a major asset manager's continued passive stake in the company.

Key Dates

Keywords

BICARA THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology